Is This Diagnostics Company a Buy After Blowing Away Earnings Estimates?
Quest Diagnostics (NYSE: DGX), a diagnostic information services provider, announced that 2021's second quarter was the first period since 2019 that its organic base testing revenues rose. That growth, it said, was the result of "new hospital lab management contracts" and strong demand for diagnostic testing as patients returned to the healthcare system.
While Quest Diagnostics' second-quarter operating results were strong, it's worth asking: Can the company maintain its momentum?
Image source: Getty images.
Source Fool.com
